http://www.depuyhipreplacementlawsuit.com/ - When DePuy Orthopaedics and its parent company, Johnson & Johnson (J&J), initiated the hip replacement recall, it crafted a compensation program that would reimburse hip recipients for the “reasonable and customary” costs associated with another surgery.

1. As Published on the DePuy Hip Replacement Website

2. When DePuy Orthopaedics and its parent company, Johnson & Johnson (J&J), initiated the hip replacement recall, it crafted a compensation program that would reimburse hip recipients for the “reasonable and customary” costs associated with another surgery. Thus, Johnson& Johnson employed Broadspire Services, a subsidiary of insurance agencyt, Crawford & Crawford.

3. The New York Times, on December 27, 2011, published an article about the reimbursement regulations of DePuy, Johnson & Johnson and Broadspire. The report claims that “things were not going smoothly for everyone who has had accepted DePuy’s payment offer.”

4. With approximately 93,000 recipients worldwide, the ASR XL Acetabular System and the ASR Hip Resurfacing System were recalled after data revealed that the devices fail prematurely in one out of eight people who have them.

5. The Director of the National Joint Replacement Registry in Australia, Dr. Stephen Graves, states that “It is a complete untruth that DePuy did not have reason to withdraw the ASR before now; we have been telling them since 2007, but they allowed it to be used on thousands of people.”

6. “ We believe we made the appropriate decision to recall at the appropriate time given the available information,” states DePuy spokeswoman, Mindy Tinsley.

7. As of March 31, 2011, the company had committed $280 million in compensatory settlements to the recalls. The company further guaranteed to “address reasonable and customary costs associated with testing and treatment.” The metal particles shed from metal-on-metal hip replacement implants may increase the amount of some metals in the blood, such as chromium and cobalt. This condition may result in genetic damage (genotoxicity) and blood poisoning (metallosis). Cancer and tumor may also be developed due to the presence of chromium and cobalt in the blood.

8. In May 2011, various medical professionals and engineers formed a group which aimed to track knee and hip implants after the DePuy hip replacement recall. “ The goal is to track the more than 700,000 total hip and knee replacement surgeries that take place in the U.S. each year and, over time, record which implants failed prematurely, requiring revision surgery to fix the original operation,” explains AJRRchairman David Lewallen, a professor of orthopedic surgery at Mayo Clinic in Rochester, Minnesota.

9. The hip replacement recall definitely prodded the manufacturer to act on the need of the consumers to have safe medical treatments and medications. With the number of duly filed DePuy lawsuit increasing worldwide, DePuy should properly face the hip replacement problems encountered by its clients. It should circulate a wide range of information regarding malfunctioning hip replacement symptoms so that its patrons would be provided with due medical attention.